- Poster presentation
- Published:
The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure
Critical Care volume 11, Article number: P222 (2007)
Introduction
The brain natriuretic peptide (BNP) is a useful index to follow-up patients with heart failure as well as a special diagnostic and prognostic tool. This study aims at investigating the impact of levosimendan in comparison with dobutamine on the BNP levels in ICU patients with decompensated heart failure related to septic shock. The role of levosimendan in septic patients is still under consideration.
Methods
Twenty-nine patients (20 males and nine females) of a 70.5 ± 9.2 average age rate with persisting left ventricular dysfunction related to severe sepsis, after receiving a 48-hour conventional treatment including inotropic agents, were randomised to either 24-hour i.v. levosimendan (0.2 γ/kg/min) (n = 15) (Group A) or dobutamine (5 γ/kg/min) (n = 14) (Group B) therapy. Serial BNP measurements were performed before, at 48 hours and 5 days later.
Results
Levosimendan therapy significantly reduced the BNP levels both in 48 hours and in 5 days as compared with dobutamine. Group A: 1,138 ± 93.7, 740.2 ± 106, 445 ± 118.3 and Group B: 1,561 ± 370.2, 1,436 ± 368, 1,850 ± 520.5, before, 48 hours and 5 days later, respectively. P = 0.025 for 48 hours and P = 0.037 for 5 days.
Conclusion
Levosimendan therapy reduces BNP levels, reflecting a beneficial haemodynamic effect on the ICU patient with septic myocardial depression.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Michalopoulou, H., Stamatis, P., Bakhal, A. et al. The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure. Crit Care 11 (Suppl 2), P222 (2007). https://doi.org/10.1186/cc5382
Published:
DOI: https://doi.org/10.1186/cc5382